Comparing buprenorphine induction experience with heroin and prescription opioid users

Journal of Substance Abuse Treatment

Volumn 43, Issue 3, 2012, Pages 285-290

  Nielsen, Suzanne ^a,b   Hillhouse, Maureen ^a   Mooney, Larissa ^a   Fahey, Jacqueline ^a   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Buprenorphine induction; Prescription opioid; Treatment

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; HYDROCODONE; ILLICIT DRUG; METHADONE; OPIATE; OXYCODONE;

ADULT; ARTICLE; DRUG ABUSE; EMPLOYMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM; SELF REPORT; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADULT; AGED; BUPRENORPHINE; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84866530085     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.12.009     Document Type: Article

References (22)

1. Barnett P.G., Rodgers J.H., Bloch D.A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001, 96:683-690.
2. Beck A.T., Steer R.A. Beck depression inventory manual 1993, Harcourt Brace & Company, New York.
3. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 2004, 73:199-207.
4. Cacciola J.S., Alterman A.I., McLellan A.T., Lin Y.T., Lynch K.G. Initial evidence for the reliability and validity of a "lite" version of the Addiction Severity Index. Drug and Alcohol Dependence 2007, 87:297-302.
5. Centre for Substance Abuse Treatment Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40 2004, Substance Abuse and Mental Health Services Administration. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration.
6. Childress A.R., McLellan A.T., O'Brien C.P. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. British Journal of Addiction 1986, 81:655-660.
7. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 2006, 81:103-107.
8. Doran C.M., Holmes J., Ladewig D., Ling W. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addiction and Related Clinical Problems 2005, 7:7-18.
9. Finch J.W., Kamien J.B., Amass L. Two-year experience with buprenorphine-naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting. Journal of Addiction Medicine 2007, 1:104-110. (110.1097/ADM.1090b1013e31809b31805df31802).
10. Johnson R.E., Strain E.C., Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 2003, 70(2, Suppl 1):S59-S77.
11. Lee J.D., Grossman E., DiRocco D., Gourevitch M.N. Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine 2009, 24:226-232.
12. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
13. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2004, CD002207.
14. McHorney C.A., Ware J.E., Lu J.F., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care 1994, 32:40-66.
15. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 2007, 22:527-530.
16. Paulozzi L.J., Budnitz D.S., Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiology and Drug Safety 2006, 15:618-627.
17. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. American Journal of Addiction 2006, 15:208-212.
18. Soyka M., Zingg C., Koller G., Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology 2008, 11:641-653.
19. Ware J.E., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Medicine Care 1992, 30:473-483.
20. Weiss R.D., Potter J.S., Copersino M.L., Prather K., Jacobs P., Provost S., et al. Conducting clinical research with prescription opioid dependence: Defining the population. American Journal on Addictions 2010, 19:141-146.
21. Wesson D.R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 2003, 35:253-259.
22. Whitley S.D., Sohler N.L., Kunins H.V., Giovanniello A., Li X., Sacajiu G., et al. Factors associated with complicated buprenorphine inductions. Journal of Substance Abuse Treatment 2010, 39:51-57.